Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04963270) looked at a medicine called satralizumab in people with a condition called generalised myasthenia gravis (gMG) — a disease that causes muscle weakness affecting things like swallowing, speaking, breathing, and everyday movements. A total of 188 people took part in the main 24-week double-blind phase, with 92 receiving a placebo (an inactive dummy injection) and 96 receiving satralizumab. Neither the participants nor the medical team knew who was getting which treatment during this phase. The main thing being measured was change in a symptom score called the MG-ADL, which rates how much the disease affects daily activities on a scale from 0 (no problems) to 24 (most severe). The reported data shows that, in the main 24-week period, participants in the placebo group who had a specific antibody type (AChR+) had an average reduction in their MG-ADL symptom score of about 2.6 points, while those receiving satralizumab had an average reduction of about 3.6 points. When looking at all participants regardless of antibody type, the reported reductions were similar — around 2.5 points for the placebo group and 3.5 points for the satralizumab group. For a separate doctor-assessed score called the QMG (also measuring disease severity, scored 0–39), the reported average reductions were approximately 1.8 points (placebo) and 3.4 points (satralizumab) in the AChR+ group, and roughly 1.7 points (placebo) and 3.4 points (satralizumab) across all participants. The reported data also shows that, at 24 weeks, about 59% of placebo participants and about 71% of satralizumab participants in the AChR+ group had their MG-ADL score reduce by at least 2 points — a threshold the researchers used to define a meaningful change. Across all participants, the figures were approximately 61% and 70% respectively. The trial also included a longer open-label extension phase of 92 weeks where all continuing participants received satralizumab, but completion figures for that phase were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39862880) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Myasthenia Gravis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have agreed to take part and signed a consent form (for teenagers, a parent or guardian must also sign, and the young person must agree to join)
- You are able to follow the study schedule and procedures
- You have been diagnosed with a type of myasthenia gravis (MG) confirmed by a specific antibody test (anti-AChR, anti-MuSK, or anti-LRP4) done at the screening visit
- Your MG symptoms score (called MG-ADL) is 5 or higher, and more than half of those points come from symptoms affecting parts of the body other than the eyes
- Your MG severity falls within a moderate-to-severe range as measured by a standard scale (MGFA Class II, III, or IV)
- You are already receiving treatment for MG and have been on a steady, unchanged dose
- If you are a woman who could become pregnant, you agree to avoid pregnancy by abstaining from sex or using reliable contraception during the study and for at least 3 months after your last dose of the study medicine
Who may not be able to join:
- You had surgery to remove your thymus gland within the past 12 months
- Your MG only affects your eyes (MGFA Class I), or you have had a severe MG crisis (MGFA Class V) in the last 3 months
- You have another medical condition that could interfere with the study (confirm with trial site)
- Your blood tests show signs of hepatitis B or hepatitis C infection
- There are signs that you have active or hidden (latent) tuberculosis, unless you are already taking medication to prevent it
- You have received a live vaccine within 6 weeks before the study starts
- You are currently pregnant or breastfeeding, or you plan to become pregnant during the study or within 3 months after your last dose
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
DB Period: Mean Change From Baseline in Total Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the AChR+ Population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.